Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA-matched transplantation: occurrence, risk factors, relapse patterns, and outcome

[1]  H. Einsele,et al.  Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations , 2022, Journal of Hematology & Oncology.

[2]  P. Vyas,et al.  Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Scott.  Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste. , 2020, Blood advances.

[4]  E. Yannaki,et al.  Isolated Extramedullary Relapse as a Poor Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  S. Fuji,et al.  Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  L. Vago,et al.  Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. , 2019, Blood.

[7]  G. Ledderose,et al.  Sequential HLA‐haploidentical transplantation utilizing post‐transplantation cyclophosphamide for GvHD prophylaxis in high‐risk and relapsed/refractory AML/MDS , 2018, American journal of hematology.

[8]  E. Estey,et al.  Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  A. Vekhoff,et al.  Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. Aljurf,et al.  Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia: clinical characteristics, incidence, risk factors and outcomes , 2018, Bone Marrow Transplantation.

[11]  H. Lazarus,et al.  Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy , 2017, Bone Marrow Transplantation.

[12]  A. Ganser,et al.  Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT , 2017, British journal of haematology.

[13]  J. Esteve,et al.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT , 2016, Bone Marrow Transplantation.

[14]  W. Hiddemann,et al.  Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma , 2015, Bone Marrow Transplantation.

[15]  N. Schmitz,et al.  Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  X. Mao,et al.  Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  S. Durrant,et al.  Is extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation associated with improved survival? , 2013, Asia-Pacific journal of clinical oncology.

[18]  G. Ledderose,et al.  Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia , 2013, Annals of Hematology.

[19]  He Huang,et al.  Clinical characteristics and outcome of isolated extramedullary relapse in acute leukemia after allogeneic stem cell transplantation: a single-center analysis. , 2013, Leukemia research.

[20]  S. Forman,et al.  Extramedullary relapse following reduced intensity allogeneic hematopoietic cell transplant for adult acute myelogenous leukemia , 2013, Leukemia & lymphoma.

[21]  T. Braun,et al.  Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes , 2013, Haematologica.

[22]  D. Blaise,et al.  Randomized study of 2 reduced‐intensity conditioning strategies for human leukocyte antigen‐matched, related allogeneic peripheral blood stem cell transplantation , 2013, Cancer.

[23]  H. Tamaki,et al.  Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome , 2012, Bone Marrow Transplantation.

[24]  N. Kröger,et al.  Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. , 2012, Blood.

[25]  M. Mohty,et al.  Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. , 2011, Cancer control : journal of the Moffitt Cancer Center.

[26]  D. Kaufman,et al.  Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[28]  A. Nagler,et al.  Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  W. Hiddemann,et al.  Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia , 2008, British journal of haematology.

[30]  W. Hiddemann,et al.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.

[31]  D. Blaise,et al.  Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first‐line treatment , 2005, Cancer.

[32]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[34]  G. Byrnes,et al.  Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy , 2000, Bone Marrow Transplantation.

[35]  C. Hemmelmann,et al.  Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. , 2019, The Lancet. Haematology.

[36]  W. Hiddemann,et al.  Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. , 2003, Blood.

[37]  E. Hoster,et al.  Brief Report Results and Discussion , 2022 .